Original Publication Date: 21 March, 2016
Publication / Source: Future Oncology
Authors: Ian D Schnadig, Richy Agajanian, Christopher Dakhil et al.
Aim: APF530, extended-release granisetron, provides sustained release for ≥5 days for acute- and delayed-phase chemotherapy-induced nausea and vomiting (CINV). We compared efficacy and safety of APF530 versus ondansetron for delayed CINV after highly emetogenic chemotherapy (HEC), following a guideline-recommended three-drug regimen. Methods: HEC patients received APF530 500 mg subcutaneously or ondansetron 0.15 mg/kg intravenously, with dexamethasone and fosaprepitant. Primary end point was delayed-phase complete response (CR: no emesis or rescue medication).
You can also view key results from the MAGIC trial in our exclusive infographic.